A similar decrease in SREBP1 was observed in another transgenic mouse model expressing human APP carrying the London mutation as the single transgene and developing amyloid pathology at a later age (Moechars et al, 1999; Fig 6B). This evidence concerns the gene APP and amyloidosis.